Showing results (91-100 of 202) with videos related to
Sort By:
Pageof 21
Archives of Internal Medicine|March 15, 2006
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002Fiona C Lampe, Jose M Gatell, Schlomo Staszewski, et al.The Journal of Infectious Diseases|April 19, 2008
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell countsHeather J Ribaudo, Daniel R Kuritzkes, Christina M Lalama, et al.HIV Clinical Trials|February 7, 2012
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug developmentBethany L Morris, Callie A Scott, Timothy J Wilkin, et al.Antimicrobial Agents and Chemotherapy|January 27, 2006
Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settingsHartmut Stocker, Charlotte Kloft, Nele Plock, et al.Antiviral Therapy|January 30, 2003
Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapyOle Kirk, Court Pedersen, Matthew Law, et al.HIV Clinical Trials|May 18, 2007
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359Richard H Haubrich, Hongyu Jiang, Ronald Swanstrom, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2014
Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patientsRoy M Gulick, Gerd Fatkenheuer, Robert Burnside, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2010
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIVTimothy W Schacker, Ronald J Bosch, Kara Bennett, et al.Lancet (London, England)|August 8, 2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialJoseph Eron, Patrick Yeni, Joseph Gathe, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 27, 2019
ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START TrialIrini Sereti, Roy M Gulick, Sonya Krishnan, et al.Pageof 21